Skip to main content

Advertisement

SpringerLink
Log in

Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole

  • Epidemiology
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Background

Adjuvant Anastrozole (ANA) for 5 years and Tamoxifen followed by Exemestane (TAM-EXE) for 2.5 years each have become acceptable alternatives to 5 years of Tamoxifen (TAM) for post-menopausal women with breast cancer. As these newer options are associated with higher drug costs as well as improved outcomes, an economic evaluation was undertaken to compare the cost-utility of ANA and TAM-EXE relative to TAM alone and to each other in terms of cost per quality-adjusted life year (QALY) gained.

Methods

A Markov model was developed to calculate monthly costs and outcomes in a hypothetical cohort of post-menopausal women with early-stage breast cancer. Baseline rates of cancer recurrence and adverse effects with TAM, and hazard ratios associated with ANA and EXE, were derived from the ATAC and IES trials. Patients received hormonal therapy for 5 years and benefit was modeled to persist 5 years beyond treatment. The analysis took a direct payer perspective with a 20-year time horizon. Costs and outcomes were discounted by 3%. Costs are in 2005 Canadian dollars.

Results

ANA and TAM-EXE were associated with increased costs and QALYs, though the cost-utility of both relative to TAM alone was strongly favourable (<$50,000/QALY). Based on an indirect comparison of ANA and TAM-EXE, using TAM alone as a common comparator, the cost-utility of ANA relative to TAM-EXE appears unfavourable.

Conclusions

Both upfront and sequential AI options were cost-effective alternatives to TAM alone, but TAM-EXE appears to be the economically preferred AI option based on its more favourable cost-utility versus ANA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Carlson RW, Brown E, Burstein HJ, Gradishar WJ, Hudis CA, Loprinzi C, Mamounas EP, Perez EA, Pritchard K, Ravdin P, Recht A, Somlo G, Theriault RL, Winer EP, Wolff AC, National Comprehensive Cancer Network (2006) NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw 4(Suppl 1):S1–26

    Google Scholar 

  2. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR (2004) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23(3):619–629

    Article  PubMed  CAS  Google Scholar 

  3. Monnier A (2006) The evolving role of letrozole in the adjuvant setting: first results from the large, phase III, randomized trial BIG 1–98. Breast 15(1 Suppl):21–29

    Article  Google Scholar 

  4. ATAC Trialists Group (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365(9453):60–62

    Article  CAS  Google Scholar 

  5. Coombes RC, Hall E, Gibson LJ, et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081–1091

    Article  PubMed  CAS  Google Scholar 

  6. Coombes RC, Hall E, Snowdon CF, et al (2004) The intergroup exemestane study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen—updated survival analysis. Breast Cancer Res Treat 88:57(abstr 3)

    Google Scholar 

  7. Ingle JN, Tu D, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE (2006) Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat [Epub ahead of print]

  8. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardly A, Price KN, Goldhirsch A; Breast International Group (BIG) 1–98 Collaborative Group (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353(26):2747–2757

    Google Scholar 

  9. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97(17):1262–1271

    Article  PubMed  CAS  Google Scholar 

  10. Sonnenberg F, Beck R (1993) Markov models in medical decision making: a practical guide. Med Decis Making 13:322–338

    Article  PubMed  CAS  Google Scholar 

  11. Potvin K, Younis T, Sellon M, Barnes P, Rayson D (2005) Patterns of Trastuzumab Use and Cost in a Single Canadian Cancer Institute. Proc ASCO 23(16S):545s, Abstract 6070

    Google Scholar 

  12. Hillner BE (2004) Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Cancer 101(6):1311–1322

    Article  PubMed  Google Scholar 

  13. Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451–1467

    Article  Google Scholar 

  14. Electronic Medicines Compendium (2005) Pharmacia, Sandwich, Kent UK http://emc.medicines.org.uk/emc/assets/c/html/displayDocPrinterFriendly.asp?documentid=2484 Cited 23 February 2006

  15. Statistics Canada (2003) Life Tables – Canada, Provinces and Territories, 1995–1997. Cat No. 84–537. Statistics Canada, 2003

  16. Will BP, Berthelot JM, Le Petit C, Tomiak EM, Verma S, Evans WK (2000) Estimates of the lifetime costs of breast cancer treatment in Canada. Eur J Cancer 36(6):724–735

    Article  PubMed  CAS  Google Scholar 

  17. Al-Fozan H, Dufort J, Kaplow M, Valenti D, Tulandi T (2002) Cost analysis of myomectomy, hysterectomy, and uterine artery embolization. Am J Obstet Gynecol 187(5):1401–1404

    Article  PubMed  Google Scholar 

  18. Lessard C, Framarin A (2003) Endometrial ablation techniques in the treatment of dysfunctional bleeding. Agence d’evaluation technologies et des modes d’intervention en sante, Quebec

  19. Skedgel C, Goeree R, Pleasance S, Thompson K, O’Brien B, Anderson D (2004) The cost-effectiveness of extended antithrombotic prophylaxis following total hip arthroplasty. Value Health 7(6):693, Abstract PCV26

    Google Scholar 

  20. Coyle D, Cranney A, Lee K, Welch V, Tugwell P (2001) Cost effectiveness of nasal calcitonin in postmenopausal women. Pharmacoeconomics 19(5):565–575

    Article  PubMed  CAS  Google Scholar 

  21. Grima D, Burge T, Becker D, Tosteson A (2002) Short-term cost-effectiveness of bisphosphonate therapies for postmenopausal osteoporotic women at high risk of fracture. P&T 27(9):448–455

    Google Scholar 

  22. Consumer Price Index (Health Care) (2005) Statistics Canada, Ottawa, Canada http://dc2.chass.utoronto.ca.ezproxy.library.dal.ca/cgi-bin/cansim2/getSeriesData.pl?s=V1870 2617&b=&e=&f=plain Cited 4 June 2005

  23. Drummond M, O’Brien B, Stoddart G, Torrance G (1997) Methods for the economic evaluation of health care programmes. Oxford Medical publications, Oxford, Great Britain

    Google Scholar 

  24. The CEA Registry (2005) Tufts-New England Medical Center, Institute for Clinical Research and Health Policy Studies http://www.hsph.harvard.edu/cearegistry/data/phaseIIpreferenceweights.pdf Cited 1 June 2005

  25. Punglia R, Kuntz K, Winer E, Weeks J, Burstein H (2005) Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol 32:5178–5187

    Article  Google Scholar 

  26. Buzdar AU, Cuzick J (2006) Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data. Clin Cancer Res. 12(3 Pt 2):1037s–1048s

    Article  PubMed  CAS  Google Scholar 

  27. Lønning PE (2006) Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2–3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Ann Oncol 17(2):217–225

    Article  PubMed  Google Scholar 

  28. Thompson D, Taylor D, Montoya E, Winer E, Weinstein M (2005) Cost-effectiveness of switching to exemestane following two-to-three years of therapy with tamoxifen in postmenopausal women with primary breast cancer. Breast Cancer Res Treat 94(S1):S218, Abstract 5037

    Google Scholar 

  29. Wilson K, Wordsworth S, Tabberer M, Lees M, Carroll D, Rea D, Coleman R (2006) Exemestane in adjuvant treatment of early breast cancer in postmenopausal women: results of a UK cost-effectiveness model. Eur J Cancer 4(2 Supplement):151, Abstract 354

    Google Scholar 

  30. Lundkvist J, Wilking N, Holmberg S, Lidgren M, Jonsson L (2006) Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2–3 years treatment with tamoxifen in Sweden. Eur J Cancer 4(2 Supplement):152, Abstract 358

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Centre for Clinical Research, Dalhousie University, 5790 University Ave, B3H 1V7, Halifax, NS, Canada

    C. Skedgel, D. Rayson & T. Younis

  2. Cancer Care Nova Scotia, Halifax, Nova Scotia, Canada

    R. Dewar

Authors
  1. C. Skedgel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Rayson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Dewar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. Younis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Skedgel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Skedgel, C., Rayson, D., Dewar, R. et al. Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole. Breast Cancer Res Treat 101, 325–333 (2007). https://doi.org/10.1007/s10549-006-9299-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-006-9299-4

Keywords

Search

Navigation